Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

The Trump administration’s effort to slash federal funding to universities has found its latest targets, with the government ...

On Friday, a federal judge permanently blocked the National Institutes of Health from implementing indirect cost caps on ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating ...

Oncology health tech firm Flatiron Health will use Massive Bio’s patient database to identify and recruit participants for ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake of new data showing the RNA therapy ...

With two attempts to merge with other companies having collapsed, Vincerx Pharma has been left with no choice but to ...